→
Johnson & Johnson has a market capitalization of $585.19B and is currently priced at $240.88, reflecting a change of +1.05% from the previous close of $238.38. The company has reported a P/E (TTM) ratio of 21.84 and a revenue growth of 6.05% year-over-year. Its EPS growth stands at 90.50%, while the return on equity (ROE) is at 32.87%. The stock's 52-week range is between $149 and $251.71.
Investors should consider the balance of growth metrics and market performance when evaluating Johnson & Johnson.
Some investors see potential in Johnson & Johnson due to its significant EPS growth of 90.50% year-over-year, which may indicate strong operational efficiency. Additionally, the company's recent acquisition of Firefly Bio for $1B could enhance its research capabilities in oncology, potentially leading to new revenue streams.
Conversely, the stock has shown limited movement despite the positive developments, as indicated by headlines questioning why the stock is 'standing still'. The current P/E ratio of 21.84 may also raise concerns for some investors regarding valuation, especially in a market with fluctuating growth expectations.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Johnson & Johnson has a market capitalization of $585.19B and is currently priced at $240.88, reflecting a change of +1.05% from the previous close of $238.38. The company has reported a P/E (TTM) ratio of 21.84 and a revenue growth of 6.05% year-over-year. Its EPS growth stands at 90.50%, while the return on equity (ROE) is at 32.87%. The stock's 52-week range is between $149 and $251.71.
Conversely, the stock has shown limited movement despite the positive developments, as indicated by headlines questioning why the stock is 'standing still'. The current P/E ratio of 21.84 may also raise concerns for some investors regarding valuation, especially in a market with fluctuating growth expectations.
Some investors see potential in Johnson & Johnson due to its significant EPS growth of 90.50% year-over-year, which may indicate strong operational efficiency. Additionally, the company's recent acquisition of Firefly Bio for $1B could enhance its research capabilities in oncology, potentially leading to new revenue streams.
Some investors see potential in Johnson & Johnson due to its significant EPS growth of 90.50% year-over-year, which may indicate strong operational efficiency. Additionally, the company's recent acquisition of Firefly Bio for $1B could enhance its research capabilities in oncology, potentially leading to new revenue streams. Conversely, the stock has shown limited movement despite the positive developments, as indicated by headlines questioning why the stock is 'standing still'. The current P/E ratio of 21.84 may also raise concerns for some investors regarding valuation, especially in a market with fluctuating growth expectations.
Johnson & Johnson has a market capitalization of $585.19B and is currently priced at $240.88, reflecting a change of +1.05% from the previous close of $238.38. The company has reported a P/E (TTM) ratio of 21.84 and a revenue growth of 6.05% year-over-year. Its EPS growth stands at 90.50%, while the return on equity (ROE) is at 32.87%. The stock's 52-week range is between $149 and $251.71.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for JNJ at helmterminal.dev/analyze/JNJ, updated continuously during US market hours. No signup required.